

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: NC2017/0001614				
CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados*. Para el caso de secuencias, anexar alineamientos)				
Palabras clave utilizadas		Fowl adenovirus serotype 9, Fadv-9, serotype 9 avian adenovirus, non-essential region, left end, 491-2782 nucleotide		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: C12N 15/861, A61K 39/12, A61K 39/145, A61K 39/245, A61K 39/215, A61K 39/112		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas	Categorías especiales de los documentos citados***
ISA (INAPI)	Corredor <i>et al.</i> (2011)	09/2011	1-17 (Pág. 443, Col. Der., líneas 8 a 18, Pág. 444, Col. Izq., líneas 10 a 15, Fig. 1, Fig. 2, Fig. 3, Pág. 445, Col. Izq., líneas 17 a 23)	Y
	Yang <i>et al.</i> (2009)	24/09/2009	1-17 (Pág. 48, Col. Izq., líneas 26 a 62, Col. Der., líneas 1 a 8)	Y
	WO 2010/058236	27/05/2010	-	A
	US 6296852	02/10/2001	-	A
	Corredor <i>et al.</i> (2010)	02/02/2010	-	A
	Deng <i>et al.</i> (2013)	08/2013	-	A
	Johnson <i>et al.</i> (2003)	20/06/2003	-	A
	Sheppard <i>et al.</i> (1998)	04/1998	-	A
EPO	Elliot (2012)	01/08/2012	-	A
*** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.		“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.		
**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.				

Literatura no patente	Corredor, J. C. & Nagy, E. 2011. Antibody Response and Virus Shedding of Chickens Inoculated with Left End Deleted Fowl Adenovirus 9-Based Recombinant Viruses. <i>AVIAN DISEASES</i>, Vol. 55 (3), Pág: 443-446. Yang, D. H., Corredor, J. C., Krell, P. J., Nagy, E. 2009. Development of fowl adenovirus 9 based vector vaccine expressing the hemagglutinin gene of an H5N1 influenza virus. Programme and Proceedings, p. 48. Oral presentations-Vaccines and viral immunology. ESVV-8th International Congress of veterinary Virology-Agosto 2009-Budapest-Hungary.
-----------------------	--

	Corredor, J. C. & Nagy, E. 2010. The non-essential left end region of the fowl adenovirus 9 genome is suitable for foreign gene insertion/replacement. <i>Virus Research</i>, Vol. 149 (2), Pág: 167-174. Deng, L., Sharif, S., Nagy, E. 2013. Oral Inoculation of Chickens with a Candidate Fowl Adenovirus 9 Vector. <i>Clinical and Vaccine Immunology</i>, Vol. 20 (8), Pág: 1189-1196. Johnson, M. A., Pooley, C., Ignjatovic, J., Tyack, S. G. 2003. A recombinant fowl adenovirus expressing the S1 gene of infectious bronchitis virus protects against challenge with infectious bronchitis virus. <i>Vaccine</i>, Vol. 21 (21-22), Pág: 2730-2736. Sheppard, M., Werner, W., Tsatas, E., McCoy, R., Prowse, S., Johnson, M. 1998. Fowl adenovirus recombinant expressing VP2 of infectious bursal disease virus induces protective immunity against bursal disease. <i>Arch Virol</i>, Vol. 143 (5), Pág: 915-930. Elliot, A. 2012. Comparing influenza virus hemagglutinin (HA) expression in three different baculovirus expression systems. Master Thesis. The University of Guelph, Canadá.
--	--

Fecha del reporte de búsqueda:	26/septiembre/2018
--------------------------------	--------------------

Búsqueda en PatBase



Username: SIC9@patbase.com
 Subaccount: Tatiana Vargas

Menu - Search - History - Session - Folder - Order Help - Logoff

#	Search query	Results	Options
9	FT=(fadv-9 and vaccin*)	6	View Browse Hits Optimise more...
8	FT=(fadv-9 and 2782)	1	View Browse Hits Optimise more...
7	FT=(fadv-9)	6	View Browse Hits Optimise more...
6	FT=(fowl and adenovirus and (491 w5 nucleotid*)	6	View Browse Hits Optimise more...
5	FT=((fadv) or ((fowl w2 adenovirus) w5 vector)) and (491))	9	View Browse Hits Optimise more...
4	[SP]: 1. a recombinant vaccine comprising a serotype 9 fowl adenovirus vector (fadv-9) having at least one exogenous nucleotide sequence inserted encoding at least one antigen of a disease of interest and replacing the adenovirus genome non-essential region, and a pharmaceutically acceptable vehicle, adjuvant and/or excipient, characterized in that the exogenous nucleotide sequence is located between the 491 and 2782 nucleotides. 2. the recombinant vaccine according to claim 1, wherein th... show full search	0	
3	FT=((fadv) or ((fowl w2 adenovirus) w5 vector)) and (non w5 essential))	9	View Browse Hits Optimise more...
2	FT=(fadv-9 or ("serotype 9 avian adenovirus") or (fowl adenovirus vector))	9	View Browse Hits Optimise more...
1	FT=(fadv-9 or ("serotype 9 avian adenovirus"))	6	View Browse Hits Optimise more...

Information Shortcuts

Command Reference
 Bibliographic data
 Textual data
 Update commands
 Operators
 Navigation / shortcuts

Search tools
 Patent Number Formats
 PatBase Thesaurus
 Classification Finder

Búsqueda en Epoquenet

[SS 2] 1 AND (SEROTYP+ 5W "9")

Results in EPODOC 2

[SS 3] ..LI



1/2 © EPODOC / EPO

- PN - [PH12017500216](#) A1 20170703
- PR - WO2014IB63809 20140808; WO2015IB55994 20150806
- AP - PH20171500216 20170203
- DT - I
- CCI - [A61K39/12](#) ; [C07K14/005](#) ; [C12N15/86](#)
- CQI - [A61K39/145](#) ; [A61K39/245](#) ; [C12N7/00](#)
- CCA - [A61K2039/5252](#) ; [A61K2039/5256](#) ; [A61K2039/545](#) ; [C12N2710/10221](#) ; [C12N2710/10234](#) ; [C12N2710/10243](#) ; [C12N2710/16034](#) ; [C12N2760/16134](#) ; [C12N2760/16171](#) ; [C12N2710/16071](#) ; [C12N2710/10271](#)
- CQA - [A61K2039/70](#)
- PA - GRUPO IND PECUARIO S A DE C V [MX]
- TI - VACCINE IN **SEROTYPE-9 FOWL ADENOVIRUS**RECOMBINANT VECTOR
- AB - A description is given of a recombinant vaccine that comprises a sero type 9 avian **adenovirus vector** (FAdV-9) with the insertion of at least one exogenous nucleotide sequence that codes for at least one antigen of a disease of interest and that replaces the non-essential region of the **adenovirus** genome, and a vehicle, adjuvant and/or excipient that is pharmaceutically acceptable, wherein the at least one exogenous nucleotide sequence that codes for at least one antigen of a disease of interest and that replaces the non-essential region of the **adenovirus** genome is located between nucleotides 491-2782. The **vector** of this vaccine is stable for production on an industrial scale. Likewise, even when this vaccine is administered in combination with a vaccine against Marek's disease, the two vaccines produce an adequate immune response that is unaffected by interference between them. Similarly, the efficacy of the recombinant vaccine is unaffected by maternal antibodies and is capable of inducing a protective response that is both early and